Increased coated-platelet levels in chronic haemodialysis patients

被引:21
作者
Valaydon, Zina S. [1 ]
Lee, Petrova [1 ]
Dale, George L. [4 ]
Januszewski, Andrzej S. [1 ]
Rowley, Kevin G. [1 ,3 ]
Nandurkar, Harshal [1 ,2 ]
Karschimkus, Connie [1 ]
Best, James D. [1 ]
Lyons, Timothy J. [5 ]
Jenkins, Alicia J. [1 ,5 ]
机构
[1] Univ Melbourne, St Vincents Hosp, Dept Med, Fitzroy, Vic 3065, Australia
[2] Univ Melbourne, St Vincents Hosp, Dept Haematol, Fitzroy, Vic 3065, Australia
[3] Univ Melbourne, Sch Populat Hlth, Ctr Hlth & Soc, Onemda VicHlth Koori Hlth Unit, Melbourne, Vic, Australia
[4] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Sect Hematol & Oncol, Oklahoma City, OK USA
[5] Univ Oklahoma, Hlth Sci Ctr, Harold Hamm Oklahoma Diabet Ctr, Oklahoma City, OK USA
基金
美国国家卫生研究院;
关键词
coated-platelet; haemodialysis; renal failure; thrombosis; vascular disease; SEROTONIN; DYSFUNCTION; ACTIVATION; INHIBITORS; FAILURE; RISK;
D O I
10.1111/j.1440-1797.2008.01026.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Aim: To determine if levels of coated-platelets, which are potentially pro-thrombotic, are increased in end-stage renal disease patients on haemodialysis, a condition associated with high cardiovascular disease risk. Methods: In a cross-sectional observational study, coated-platelet levels were measured by flow cytometry in 25 end-stage renal failure haemodialysis patients and 25 controls without renal disease. Associations between coated-platelet levels and clinical and biochemical factors relevant to renal and cardiovascular disease were evaluated. Results: Mean +/- SD coated-platelet levels were higher in the dialysis group than in the control group (39.3 +/- 14.3% vs 30.9 +/- 10.3%, P = 0.02). The number of subjects with high coated-platelet levels (>40%) was larger in the dialysis than in the control group (13/25 vs 4/25, chi(2) test, P = 0.007). On univariate analysis, coated-platelet levels correlated with serum C-reactive protein levels in renal failure (r = 0.47, P = 0.02) and inversely with white cell count in the control group (r = -0.60, P = 0.001). Coated-platelet levels were higher in dialysis patients reporting alcohol abstinence than among those reporting 'social' drinking (44.3 +/- 12.6 vs 28.8 +/- 13.5%, P = 0.01). Age, gender, body weight, smoking, diabetes, lipid levels and lipid-lowering drugs were not associated with coated-platelet levels (all P > 0.05). Conclusion: Coated-platelet levels are increased in haemodialysis patients relative to subjects with normal renal function, and are related to inflammation and alcohol abstinence. Other vascular risk factors, such as smoking, lipids and diabetes, were not related to coated-platelet levels. Coated-platelets may be implicated in the increased thrombosis and vascular risk in end-stage renal disease.
引用
收藏
页码:148 / 154
页数:7
相关论文
共 23 条
[1]   Platelet surface receptor activation in patients with chronic renal failure on hemodialysis, peritoneal dialysis and those with successful kidney transplantation [J].
Ballow, A ;
Gader, AMA ;
Huraib, S ;
Al-Husaini, K ;
Mutwalli, A ;
Al-Wakeel, J .
PLATELETS, 2005, 16 (01) :19-24
[3]   Platelet dysfunction in renal failure [J].
Boccardo, P ;
Remuzzi, R ;
Galbusera, M .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2004, 30 (05) :579-589
[4]  
Brooks MB, 2006, BLOOD, V108, p328A
[5]   The relative dosing of epoetin alfa and darbepoetin alfa in chronic kidney disease [J].
Cremieux, Pierre-Yves ;
Van Audenrode, Marc ;
Lefebvre, Patrick .
CURRENT MEDICAL RESEARCH AND OPINION, 2006, 22 (12) :2329-2336
[6]   Coated-platelets: an emerging component of the procoagulant response [J].
Dale, GL .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2005, 3 (10) :2185-2192
[7]   Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface [J].
Dale, GL ;
Friese, P ;
Batar, P ;
Hamilton, SF ;
Reed, GL ;
Jackson, KW ;
Clemetson, KJ ;
Alberio, L .
NATURE, 2002, 415 (6868) :175-179
[8]  
Guyton AC., 2000, Transport of oxygen and carbon dioxide in the blood and body fluids, no Textbook of Medical Physiology, V10th, P463
[9]   Glycoprotein IIb/IIIa inhibitors increase COAT-platelet production in vitro [J].
Hamilton, SF ;
Miller, MW ;
Thompson, CA ;
Dale, GL .
JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 2004, 143 (05) :320-326
[10]   Paroxetine decreases platelet serotonin storage and platelet function in human beings [J].
Hergovich, N ;
Aigner, M ;
Eichler, HG ;
Entlicher, J ;
Drucker, C ;
Jilma, B .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 68 (04) :435-442